Barclays PLC Ac Immune Sa Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Ac Immune Sa stock. As of the latest transaction made, Barclays PLC holds 490 shares of ACIU stock, worth $1,739. This represents 0.0% of its overall portfolio holdings.
Number of Shares
490Holding current value
$1,739% of portfolio
0.0%Shares
15 transactions
Others Institutions Holding ACIU
# of Institutions
47Shares Held
28.2MCall Options Held
150KPut Options Held
12.4K-
Bvf Inc San Francisco, CA19.5MShares$69.3 Million2.35% of portfolio
-
Black Rock Inc. New York, NY2.61MShares$9.26 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA1.69MShares$6.01 Million0.42% of portfolio
-
Wells Fargo & Company San Francisco, CA1.11MShares$3.93 Million0.0% of portfolio
-
Platinum Investment Management LTD Sydney Australia 2000, C3952KShares$3.38 Million0.17% of portfolio
About AC Immune SA
- Ticker ACIU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,413,504
- Market Cap $296M
- Description
- AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...